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Background Prior epidemiologic studies on the 
association between diabetes and gastric cancer risk 
provided inconclusive findings, while traditional, aggregate 
data meta-analyses were characterized by high between-
study heterogeneity.
Objective To investigate the association between type 2 
diabetes and gastric cancer using data from the ‘Stomach 
Cancer Pooling (StoP) Project’, an international consortium 
of more than 30 case–control and nested case–control 
studies, which is large and provides harmonized definition 
of participants’ characteristics across individual studies. 
The data have the potential to minimize between-study 
heterogeneity and provide greater statistical power for 
subgroup analysis.
Methods We included 5592 gastric cancer cases and 
12 477 controls from 14 studies from Europe, Asia, North 
America, and South America in a two-stage individual-
participant data meta-analysis. Random-effect models 
were used to estimate summary odds ratios (ORs) and 
their corresponding 95% confidence intervals (CIs) by 
pooling study-specific ORs.
Results We did not find an overall association between 
diabetes and gastric cancer (pooled OR = 1.01, 95% CI, 
0.94–1.07). However, the risk of cardia gastric cancer was 
significantly higher among individuals with type 2 diabetes 
(OR = 1.16, 95% CI, 1.02–1.33). There was no association 
between diabetes and gastric cancer risk in strata of 
Helicobacter pylori infection serostatus, age, sex, BMI, 
smoking status, alcohol consumption, fruit/vegetable intake, 
gastric cancer histologic type, and source of controls.
Conclusion This study provides additional evidence that 
diabetes is unrelated to gastric cancer overall but may be 
associated with excess cardia gastric cancer risk. European 
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Introduction
In 2020, it was estimated that more than one million new 
cases of gastric cancer (or stomach cancer) were diagnosed 
worldwide and approximately 769 000 deaths were attrib-
utable to the disease, making it the fifth most common 
human malignancy and the fourth leading cause of cancer 
death (Sung et al., 2021). Globally, the age-standardized 
incidence of gastric cancer among males and females 
were 15.8 and 7.0 per 100 000, respectively, while the 
respective mortality rates were 11.0 and 4.9 per 100 000 
(Sung et al., 2021)
Helicobacter pylori is the major human stomach carcin-
ogen [International Agency for Research on Cancer 
(IARC), 1994]. One of the proposed mechanisms for the 
initiation and development of gastric cancer is oxidative 
stress via inflammation induced by infection with H. 
pylori, which leads to DNA damage by reactive oxygen 
species and subsequent tissue neoplasia (Vigneri et al., 
2009). Because metabolic syndromes/disorders, including 
obesity and type 2 diabetes mellitus, are also associated 
with low-grade systemic pro-inflammation, they may as 
well play important roles in gastric cancer carcinogenesis 
(Vigneri et al., 2009).
While epidemiologic studies have shown that individuals 
with diabetes mellitus have an increased risk of cancer in 
various organs/tissues including the pancreas (Huxley et 
al., 2005), breast (Liao et al., 2011), endometrium (Friberg 
et al., 2007), colon/rectum (Larsson et al., 2005), and liver 
(El-Serag et al., 2006), data on the association between 
diabetes and gastric cancer risk are inconclusive. A 
meta-analysis by Tian et al. (2012) found a modest and 
marginally significant association between diabetes and 
the risk of gastric cancer [relative risk (RR) = 1.11, 95% CI, 
1.00–1.24, I2 = 79.5%]. In a stratified analysis, this associa-
tion was stronger in studies conducted in Asia (RR = 1.19, 
95% CI, 1.07–1.32, I2 = 29.8%) and on patients with type 2 
diabetes (RR = 1.14, 95% CI, 1.01–1.30, I2 = 84.8%).
In another meta-analysis of 21 observational studies, includ-
ing 4 case–control and 17 cohort studies, Ge et al. (2011) 
reported no significant association between diabetes and 
gastric cancer (RR = 1.09, 95% CI, 0.98–1.22, I2 = 81.2%). In 
stratified analysis, diabetic women were found to have 18% 
excess risk of gastric cancer (RR = 1.18, 95% CI, 1.01–1.39), 
whereas no association was observed in men. Also, a recent 
meta-analysis of 22 studies and 13 538 incident gastric can-
cer cases (Miao et al., 2017) found no association between 
diabetes mellitus and gastric cancer (RR = 1.10, 95% CI, 
0.94–1.29, I2 = 22.9% in men and 1.00 (0.90–1.11), I2 = 97.2% 
in women). However, in stratified analysis by geographic 
region, a significant positive association was found between 
diabetes and gastric cancer among women in Western coun-
tries (RR = 1.31, 95% CI, 1.09–1.57, I2 = 0.0%). Furthermore, 
this association was stronger among nonsmokers (RR = 1.58, 
95% CI, 1.04–2.39, I2 = 91.1% in men and 1.60 (1.02–2.50), 
I2 = 90.5% in women).
While heterogeneity in meta-analysis is often ines-
capable, between-study variability in these aggregate 
meta-analyses was too high that a different approach 
is needed to summarize the true relationship between 
diabetes mellitus and gastric cancer risk. The Stomach 
Cancer Pooling (StoP) Project, an international consor-
tium of more than 30 epidemiological gastric cancer 
studies, provides a unique opportunity to perform such 
type of study, through individual-level data that were 
harmonized to produce a more homogeneous definition 
of participants characteristics (Pelucchi et al., 2015). In 
addition, the large dataset provides strong power for 
valid subgroup analyses. In the current study, we inves-
tigated the association between type 2 diabetes mellitus 
and gastric cancer by pooling individual-level data from 
case–control studies in the StoP Project consortium.
Methods
Study population and sample size
Details of the purpose and procedures of the StoP pro-
ject have been provided elsewhere (Pelucchi et al., 2015). 
Briefly, data for the current analysis were based on the 
second release of the StoP project consortium data, 
which includes 31 gastric cancer case–control and nested 
case–control studies worldwide. A total of 14 participating 
studies with data on type 2 diabetes were included in our 
analysis. Four of the studies were from Italy (Buiatti et 
al., 1989; La Vecchia et al., 1995; Lucenteforte et al., 2008; 
De Feo et al., 2012), two from Spain (Santibañez et al., 
2012; Castaño-Vinyals et al., 2015), one each from Greece 
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(Lagiou et al., 2004), Russia (Zaridze et al., 2000), China 
(Setiawan et al., 2005), and Japan (Machida-Montani et 
al., 2004), and two each were from the USA (Zhang et 
al.,1999; one is unpublished) and Brazil (Hamada et al., 
2002; Nishimoto et al., 2002). These constituted a total of 
5592 gastric cancer cases and 12 477 controls. Only one 
study had published a report on the association between 
diabetes and gastric cancer previously (La Vecchia et al., 
1995). The original data from each study were obtained 
after a signed data transfer agreement was given by the 
principal investigators. The consortium harmonized all 
data based on a predetermined format.
The University of Milan Institutional Review Board 
(IRB) provided the ethical approval for the StoP project 
(reference 19/15 – 01 April 2015). Participating studies 
were approved by their local IRBs.
Study outcome
Cases were individuals with histologically confirmed 
incident gastric cancer. All the studies included data on 
cancer anatomical subsite (cardia and noncardia) and his-
tologic subtype (i.e. intestinal, diffuse, and others, includ-
ing mixed, undifferentiated, and unclassified type) except 
a Chinese study (Setiawan et al., 2005) (for both subsite 
and histologic type) and three other studies (La Vecchia et 
al., 1995; Lagiou et al., 2004; Machida-Montani et al., 2004) 
which did not include information on cancer histology. 
The outcome for our main analysis was any type of gastric 
cancer, regardless of a subsite or histologic classification. 
We performed additional analyses with each gastric can-
cer histologic type and subsite as (polytomous) outcome.
Controls were recruited from the same source population 
and within the same periods as the cases. In nine studies, 
the controls were selected at the same health facility as 
the cases and, depending on the study, included patients 
with various noncancer conditions. The Japanese study 
(Machida-Montani et al., 2004) selected controls among 
participants in a health checkup program. Three studies 
recruited controls from the general population (Buiatti 
et al., 1989; Setiawan et al., 2005; Castaño-Vinyals et al., 
2015), while one study (Hamada et al., 2002) had a mixed 
source of controls (58% from a hospital near the cases 
source and 42% from the community).
Exposure
Data on the history of type 2 diabetes mellitus (diag-
nosed by a health professional or treated) were collected 
using a structured questionnaire in all 14 studies. The 
questionnaires were administered by trained interview-
ers in all the studies except the Russian study (Zaridze et 
al., 2000) – for which it was self-administered – and two 
others (Zhang et al., 1999; Machida-Montani et al., 2004) 
– for which the information on the procedure used to 
administer the questionnaire was not provided. Exposure 
data were collected in the same way and within the same 
period for cases and controls in all the studies.
Statistical analysis and covariates
We adopted the two-stage individual-participant data 
pooling approach (Burke et al., 2017). At the initial stage, 
we used unconditional logistic regression to estimate odds 
ratios (ORs) and the corresponding 95% confidence inter-
vals (95% CIs) for the association between diabetes and 
gastric cancer in each study, using maximum likelihood 
method. Depending on availability (no more than 30% 
missing data) and feasibility, the logistic regression mod-
els were adjusted for age (i.e. <55, 55–65, and >65 years), 
race/ethnicity (i.e. White, Black/African American, Asian, 
Hispanic/Latino, and other races), sex, BMI (i.e. <18.5, 
18.5–24.9, 25–29.9, and ≥30 kg/m2), alcohol consumption 
(i.e. never, low, and moderate/high), tobacco smoking sta-
tus (i.e. never, former, and current), H. pylori infection 
serostatus, history of gastric ulcer, fruit/vegetable intake 
(using study-specific tertiles), and study site (for studies 
with multiple sites). Some variables were re-categorized to 
avoid scant data in some studies, and also for the stratified 
analyses. Any implausibility or inconsistency in observa-
tions was reconciled by the investigators for each individ-
ual study.
We replaced the occasional missing data in study covari-
ates using multiple imputations by fully conditional spec-
ification (Liu and De, 2015). Under the assumption of 
missing at random, 10 imputed datasets were generated 
for each study, with the missing observations replaced 
with values selected from the separate conditional dis-
tribution of each imputed variable. A logistic regression 
model was then fitted on each of the 10 imputed datasets 
to obtain estimates, which were combined using Rubin’s 
rule (Rubin, 2004) to produce regression coefficient and 
corresponding standard error for each study. The impu-
tation models contained the same set of covariates (and 
the outcome) as the analysis models. The resulting 
study-specific regression coefficients were then com-
bined in the second (pooling) stage using inverse-vari-
ance weighted random effect models (Burke et al., 2017) 
to produce summary ORs and 95% CI estimates.
For the analysis with cancer anatomical subsite and his-
tologic type as outcomes, we fitted polytomous logistic 
regression models for each study in the analysis phase of 
the first stage, following multiple imputations. Between-
study heterogeneity was assessed using the Method-of-
Moments estimator and quantified using I2 (proportion 
of total model variance due to between-study variability) 
(DerSimonian and Laird, 1986). We performed subgroup 
analyses to evaluate possible differences in the associa-
tion between type 2 diabetes and gastric cancer across 
strata of sex, age, BMI (i.e. <25 and ≥25), smoking sta-
tus, alcohol consumption, fruit/vegetable intake, H. pylori 
infection serostatus, cancer subsite, cancer histological 
subtype, geographical region and source of controls (i.e. 
hospital versus general population). The study with the 
mixed source of controls (Nishimoto et al., 2002) was 
considered to have used hospital controls only. Statistical 
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significance of differences across strata was assessed in a 
meta-regression model.
We conducted a number of sensitivity analyses to assess the 
robustness of our results, even though the two-stage analy-
sis method was adopted a priori to avoid bias (Burke et al., 
2017), and we took steps to check the quality of the imputed 
data, including examination of the differences between the 
observed, imputed and completed datasets and comparison 
of their distributions using Kernel density plots (Liu and 
De, 2015). First, we fitted a single unconditional, fixed-effect 
logistic regression model using the entire data, controlling 
for study and other covariates that were available across all 
the studies. Missing data were also replaced in this analysis 
using the same approach as the main analysis. Second, we 
restricted the main analysis to studies that scored at least 
six on the Newcastle–Ottawa scale (NOS) for assessing 
the quality of case–control studies (Wells et al., 2011), [all 
except one (Lagiou et al., 2004)] to see if study quality had 
any impact on our results. To rule out the potential effect of 
differences in exposure data collection on our analysis, we 
excluded the study that used a self-administered question-
naire to collect data on the history of diabetes (Zaridze et al., 
2000) and two others (Zhang et al., 1999; Machida-Montani 
et al., 2004) for which usage of professional interviewers 
to administer the questionnaire could not be confirmed. 
Finally, to rule out potential misclassification of H. pylori 
infection serostatus among cases, we included only H. pylori 
seropositive controls in the logistic model for the two-stage 
main analysis, under the assumption that H. pylori infection 
was a necessary cause of gastric cancer.
The LOGISTIC, MI, and MI ANALYZE procedures 
in SAS (version 9.4) were performed in the first stage of 
the analysis, using a macro specifically developed for this 
purpose. The METAREG package in Stata (version 16) 
was used to fit the random-effect and meta-regression 
models in the second stage (the pooling stage).
Results
Participants’ characteristics
The current analysis included 5592 gastric cancer cases 
and 12 477 controls. Table  1 reports selected charac-
teristics of the participating studies. European studies 
account for two-thirds of the participants (68.7%), and 
Italy had the largest proportion among countries (35.5%). 
The rest of the participants were from Asia (10.4%), 
North America (16.9%), and South America (4.0%).
The summary of key sociodemographic and health 
characteristics of the cases and controls is presented in 
Table 2. A larger proportion of controls (8.8%) than cases 
(7.3%) had type 2 diabetes. Mean age at study entry was 
slightly higher for cases (62.2 years) than for controls 
(60.4 years). Gastric cancer cases were also more likely to 
be male patients, of low socioeconomic status, moderate 
to high consumers of alcohol, current smokers as well as 
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Association between type 2 diabetes mellitus and 
gastric cancer
Table  3 shows the pooled ORs and 95% CIs for the 
association between gastric cancer and diabetes for all 
participants – also shown in (Fig. 1), and stratified by age, 
BMI, smoking status, drinking frequency, fruits/vegeta-
ble intake, H. pylori infection serostatus, study geograph-
ical location, cancer anatomical site, histologic subtype 
as well as type (source) of controls. Overall, compared 
to diabetes-free individuals, there was no association 
between diabetes and gastric cancer (pooled OR = 1.01, 
95% CI, 0.94–1.07).
Pooled OR estimates were significantly different 
by cancer anatomical site (P
heterogeneity
 = 0.04). Those 
with diabetes had a significantly higher risk of car-
dia gastric cancer compared to those without diabetes 
(OR = 1.16, 95% CI, 1.02–1.33), while no association 
was observed between diabetes and noncardia gastric 
cancer (OR = 1.03, 95% CI, 0.95–1.12). We did not find 
a significant difference in the association across the 
strata of H. pylori infection serostatus (P
heterogeneity
 = 0.48), 
cancer histological type (P
heterogeneity
 = 0.55), age 
(P
heterogeneity
 = 0.42), sex (P
heterogeneity
 = 0.37), BMI 
(P
heterogeneity
 = 0.49), smoking status (P
heterogeneity
 = 0.64), 
alcohol consumption (P
heterogeneity
 = 0.32), fruit/vegeta-
bles intake frequency (P
heterogeneity
 = 0.36), geographi-
cal location (P
heterogeneity
 = 0.43), and source of controls 
(P
heterogeneity
 = 0.09). Moreover, these within strata effects 
were largely similar to that from the main analysis, and 
none was statistically significant.
Sensitivity analysis
Our analysis using a single, fixed-effect logistic regression 
model for the whole data, controlling for study and other 
covariates, yielded similar results as the main, two-stage 
analysis (OR = 0.99, 95% CI, 0.94–1.08). Also, the results 
from the main analysis did not change appreciably after 
excluding one study with a score of only 5 on the NOS 
(OR = 1.01, 95% CI, 0.94–1.07), as well as following the 
removal from the analysis of three studies which either 
used a self-administered questionnaire to assess diabe-
tes history or had unverified means of administering the 
questionnaire (OR = 1.01, 95% CI, 0.95–1.09). Similarly, 
the model containing only H. pylori seropositive con-
trols did not differ from the model with all the controls 
included (OR = 1.00, 95% CI, 0.94–1.12).
Discussion
In this pooled analysis of individual-level data on 5592 
gastric cancer cases and 12 477 controls from 14 studies 
within the StoP consortium, we found a null association 
between type 2 diabetes and gastric cancer risk. When 
the analysis was stratified by cancer subsite, we found an 
increased risk of gastric cancer among patients with car-
dia tumors. The null association remained, and was con-
sistent, across strata of H. pylori infection serostatus, sex, 
age, BMI, smoking status, alcohol consumption, fruit/
vegetables intake, geographical location, cancer histolog-
ical type, and source of controls.
Table 2 Distribution of cases and controls by selected covariates 
in the current analysis
 Cases (n = 5592) Controls (n = 12 477)
Diabetes   
 No 5064 (90.6) 11 246 (90.1)
 Yes 408 (7.3) 1096 (8.8)
 Missing 120 (2.2) 135 (1.1)
Age (mean ± SD) 62.2 ± 10.8 60.4 ± 11.8
Age categories (years)   
 ≤55 1423 (25.5) 3947 (31.6)
 55–65 1538 (27.5) 3372 (27.0)
 ≥65 2631 (47.1) 5158 (41.3)
BMI   
 ≤18.5 169 (3.0) 184 (1.5)
 18.5–25 2066 (37.0) 4202 (33.7)
 25–30 1400 (25.0) 3907 (31.3)
 ≥30 1099 (19.7) 2151 (17.2)
 Missing 858 (15.3) 2033 (16.3)
Sex   
 Male 3603 (64.4) 7579 (60.7)
 Female 1989 (35.6) 4898 (39.3)
Race/ethnicity   
 White 2333 (41.7) 7108 (57.0)
 Black/African American 88 (1.6) 217 (1.7)
 Asian 105 (1.9) 199 (1.6)
 Hispanic/Latino 56 (1.0) 73 (0.6)
 Other 13 (0.2) 36 (0.3)
 Missing 2997 (53.6) 4844 (38.8)
Education (completed)   
 Less than high school 2449 (43.8) 3285 (26.3)
 High school 1521 (27.2) 44 644 (37.2)
 College graduate 419 (7.5) 1535 (12.3)
 Missing 1203 (21.5) 3013 (24.2)
Socioeconomic status   
 Low 3096 (55.4) 5464 (43.8)
 Intermediate 1794 (32.1) 4529 (36.3)
 High 594 (10.6) 2151 (17.2)
 Missing 108 (1.9) 333 (2.7)
Smoking   
 Never 2333 (41.7) 5478 (44.0)
 Former 1458 (26.1) 3482 (28.0)
 Current 1723 (30.8) 3387 (27.2)
 Missing 78 (1.4) 130 (1.0)
Drinking   
 Never 1173 (21.0) 3469 (28.0)
 Low 711 (12.7) 1474 (12.0)
 Moderate 1623 (29.0) 3126 (25.1)
 High 854 (15.3) 1665 (13.3)
 Missing 1231 (22.0) 2743 (22.0)
History of gastritis   
 No 2466 (44.1) 6017 (48.2)
 Yes 711 (12.7) 586 (4.7)
 Missing 2415 (43.2) 5874 (47.1)
History of gastric ulcer   
 No 2869 (51.3) 5075 (40.7)
 Yes 407 (7.3) 238 (2.0)
 Missing 2316 (41.4) 7164 (57.4)
History of peptic ulcer   
 No 2055 (36.8) 7298 (58.5)
 Yes 852 (15.2) 975 (7.8)
 Missing 2685 (48.0) 4204 (33.7)
Vegetable and fruit intake   
 Low 1487 (26.6) 2754 (22.1)
 Intermediate 1494 (26.7) 3181 (25.5)
 High 1774 (31.7) 3749 (30.1)
 Missing 837 (15.0) 2793 (22.3)
H. Pylori seroprevalence   
 Negative 377 (6.7) 728 (5.8)
 Positive 891 (16.0) 2601 (21.0)
 Missing 4324 (77.3) 9148 (73.3)
n: count.
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Our results add to the growing evidence on the potential 
role of diabetes in gastric cancer pathogenesis. Consistent 
with our finding, some recent (aggregate-data) meta-anal-
yses also found a minor direct but nonstatistically signif-
icant overall association between type 2 diabetes and 
gastric cancer; which was; however, significant for cer-
tain subgroups among the participants (Ge et al., 2011; 
Marimuthu et al., 2011; Miao et al., 2017). Only one of the 
meta-analyses (Ge et al., 2011) included any of the stud-
ies in this analysis (94% of cancer cases from one of the 
Italian studies) (La Vecchia et al., 1995). However, other 
meta-analyses (Tian et al., 2012; Yoon et al., 2013) and 
a recent large cohort study (Cheung et al., 2019) found 
overall significant positive associations. The differences 
between our results and those from other studies could 
be due to dissimilarities in design, analysis approach, or 
between-study heterogeneity. For example, Cheung et al. 
(2019) used a cohort design with homogenous population 
who previously received H. pylori eradication therapy. 
They also controlled for more potential confounders than 
included in our models and performed propensity score 
analysis. Lack of adjustment for use of medications in our 
models, such as metformin, aspirin, and statins, which are 
known to have an inverse association with gastric cancer 
(Currie et al., 2009; Singh and Singh, 2013; Ye et al., 2013; 
Li et al., 2018), could have biased our results towards the 
Table 3 Pooled odds ratios (ORs) and 95% confidence intervals (CIs) for the association between diabetes and gastric cancer, stratified 
by selected characteristics in the current analysis
 Diabetes   
 No Yes   




Overall 4697/10828 375/1060 1.01 (0.94–1.07) 0.73  
Sex     0.37
 Men 3365/6803 265/701 1.06 (0.97–1.16) 0.53  
 Women 1799/4443 143/395 0.94 (0.84–1.05) 0.80  
Age (years)     0.42
 ≤55 1353/3801 44/112 1.09 (0.88–1.35) 0.81  
 >55–<65 1399/3050 104/283 1.04 (0.85–1.25) 0.17  
 ≥65 2312/4395 260/701 1.00 (0.90–1.09) 0.62  
BMI (kg/m2)b     0.49
 <25 2112/4135 120/245 0.97 (0.85–1.12) 0.43  
 ≥25 2158/5254 225/686 1.04 (0.94–1.15) 0.65  
Smoking status     0.64
 Never 2096/4936 183/476 1.01 (0.90–1.13) 0.39  
 Former 1298/3066 131/400 1.06 (0.93–1.20) 0.75  
 Current 1601/3141 88/203 1.01 (0.86–1.18) 0.95  
Alcohol consumptionc     0.32
 Never 1072/3073 101/391 0.88 (0.72–1.07) 0.52  
 Low 665/1398 6/73 1.17 (0.85–1.61) 0.12  
 Moderate/high 2284/4417 190/371 1.10 (0.91–1.33) 0.08  
Fruit/vegetable intaked     0.36
 Low 1358/2482 86/239 1.00 (0.86–1.16) 0.61  
 Intermediate 1368/2869 103/274 1.02 (0.89–1.18) 0.83  
 High 1582/3396 147/305 1.03 (0.88–1.26) 0.27  
H. pylori serostatuse     0.48
 Positive 695/2235 87/358 1.02 (0.90–1.15) 0.59  
 Negative 289/658 30/69 0.94 (0.71–1.25) 0.36  
Geographic region     0.44
 Europe 3252/7933 314/880 1.02 (0.94–1.10) 0.64  
 Asia 734/882 21/24 1.12 (0.86–1.46) 0.31  
 Americas 1078/2431 73/192 0.93 (0.80–1.08) 0.65  
Cancer subsitef     0.03
 Cardia 533/10 405 56/1048 1.16 (1.02–1.33) 0.37  
 Noncardia 3283/10 405 304/1048 1.03 (0.95–1.12) 0.57  
Histological typeg     0.55
 Intestinal 1054/5963 130/798 1.07 (0.96–1.20) 0.42  
 Diffuse 625/5963 56/798 1.00 (0.86–1.17) 0.47  
 Other 594/5963 53/798 1.02 (0.86–1.20) 0.97  
Control type     0.09
 Hospital 3194/6688 227/467 0.95 (0.87–1.04)  0.77  
 Population 1870/4558 181/629 1.07 (0.97–1.18) 0.90  
CI, confidence interval; OR, odds ratio.
aPooled ORs were obtained using random-effects models. ORs were adjusted, when possible (in a study), for age, race/ethnicity, sex, BMI, socioeconomic status, 
tobacco smoking status, level of alcohol consumption, frequency of fruit/vegetable intake, history of gastric ulcer, and study site (for multicenter studies).
bVariable was not available for Brazil 1, Brazil 2, Italy 3, and USA 2 studies.
cVariable was not available for China, Italy 3, Russia, and Spain 1 studies.
dVariable was not available/not usable for USA 2, Brazil 1, and Brazil 2 studies.
eStudies considered: Brazil 1, Brazil 2, Japan, Russia, and Spain 1. Italy 3 excluded because all controls in the study had missing data on H. pylori infection serostatus.
fVariable was not available/not usable for Brazil 2, China, and Greece studies.
gStudies considered: Italy 2, Italy 3, Italy 4, Russia, Spain 1, Spain 2, and USA 1.
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null. This is because diabetic patients would more likely 
have required therapy with these drugs. But, like our 
study, Cheung et al. (2019) also found a positive associ-
ation between diabetes mellitus and cancers located in 
the cardia region of the stomach. Our analysis improved 
on traditional meta-analyses by pooling individual-level 
data and using the same definition of variables across 
individual studies, which probably reduced between-
study heterogeneity in our results. But the meta-analyses 
by Yoon et al. (2013) and Tian et al. (2012), which also 
found a significant positive association between diabetes 
and gastric cancer, were based on aggregate data. The 
latter study (Tian et al., 2012) was characterized by very 
high between-study heterogeneity (I2 = 84.8% for type 
Fig. 1
Study-specific and pooled odds ratios and their respective 95% confidence intervals for the association between diabetes and gastric cancer risk 
in the Stomach Cancer Pooling (StoP) Project Consortium. CI, confidence interval.
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2 diabetes mellitus and 79.5% for any type of diabetes 
mellitus). Also, only two studies in the work by Yoon et 
al. (2013) controlled for H. pylori infection status in their 
analyses. Nevertheless, regardless of the statistical signif-
icance, the positive direction of the association reported 
by most published meta-analyses to date suggests dia-
betes could be, potentially, an independent risk factor 
for gastric cancer. And our study, among the first pooled 
analyses of individual data to evaluate the impact of type 
2 diabetes on gastric cancer risk, also showed a similar 
trend for cardia cancer.
Of importance, we investigated the effect of diabetes 
mellitus on gastric cancer risk across strata of key covar-
iates. Our study is the first meta-analysis – to the best 
of our knowledge – to evaluate the association accord-
ing to gastric cancer subsite and H. pylori infection sta-
tus by pooling individual-level data from many studies. 
To date, only four reports have been published on the 
association by gastric tumor location (Lin et al., 2011; 
Kim et al., 2016; Cheung et al., 2019; Zheng et al., 2019). 
None of them included as many gastric cancer cases as 
we had in our analysis. Consistent with our results, Lin et 
al. (2011) and, more recently, Cheung et al. (2019) found 
a significantly higher risk of cardia gastric cancer among 
individuals with diabetes, with respective hazard ratios 
and 95% CIs of 1.89 (1.43–2.50) and 3.5 (1.45–7.97). On 
the other hand, Kim et al. (2016) and Zheng et al. (2019) 
each reported a null association (hazard ratio = 0.64, 95% 
CI, 0.14–2.94; and hazard ratio = 0.94, 95% CI, 0.57–1.54, 
respectively). There are several differences between 
these studies and ours that might explain why the results 
differ. Both studies used cohort design and included 
fewer gastric cancer cases. Moreover, the participants in 
Kim et al. (2016) study included individuals who visited 
a hospital for a routine checkup, who were possibly less 
prone to risky behaviors regarding both diabetes mellitus 
and gastric cancer, such as sedentary lifestyle, smoking, 
and alcohol intake. While Zheng et al. (2019) combined 
diabetic patients and those with prediabetes in the same 
exposure group in their analysis.
The link between type 2 diabetes mellitus and gastric 
cancer, in general, is still not fully understood, but several 
potential biological explanations have been suggested, 
including shared risk factors (such as obesity); hyperin-
sulinemia and resistance to insulin; H. pylori infection; 
comorbidities (e.g. via diet or lifestyle changes); use of 
medications (e.g. metformin, aspirin, statins, and insu-
lin) and hyperglycemia (Lorenzi et al.,1986; Dandona 
et al.,1996; Pollak, 2012; Wieser et al., 2013; Tseng and 
Tseng, 2014; Cheung et al., 2018). It is also not clear what 
might be responsible for the difference being observed in 
the cardia and noncardia gastric cancer risk, but a recent 
hypothesis suggests that the answer might lie in the dis-
tinct cancer etiopathogenetic mechanisms for the two 
stomach subsites (Cheung et al., 2019). H. pylori infec-
tion (through atrophic gastritis and hypochlorhydria), 
low socioeconomic status, and dietary factors are known 
to be associated more with noncardia gastric cancers. 
Whereas obesity (particularly severe type) and gastro-
esophageal reflux disease (GERD) are risk factors that 
are almost unique to cardia cancers (Karimi et al., 2014). 
The observed higher risk of cardia gastric cancer among 
individuals with type 2 diabetes might be due to their 
greater predisposition to obesity and GERD (Rawla and 
Barsouk, 2019). Furthermore, treating H. pylori infection 
might improve corpus inflammation, thereby restoring 
gastric acid production and compound GERD (Cheung 
et al., 2019). However, Lin et al. (2011) did not find any 
difference in the risk of proximal gastric adenocarcinoma 
due to diabetes across strata of BMI, suggesting that 
other factors independent of obesity could be involved 
in the pathogenesis of cardia cancer. Further research is 
needed to test these hypotheses using more comprehen-
sive data on obesity and H. pylori infection than used in 
this analysis and other published studies, to be collected 
long before cancer diagnosis.
Our study is also among the few to have examined poten-
tial differences in gastric cancer risk due to diabetes 
according to strata of H. pylori infection (Jun et al., 2006; 
Ikeda et al., 2009). Like our study, Jun et al. (2006) found 
a similar, null association between diabetes mellitus and 
gastric cancer among both H. pylori positive and negative 
individuals. However, Ikeda et al. (2009) reported a sig-
nificant increase in gastric cancer risk among H. pylori-in-
fected diabetic patients who had baseline glycated 
hemoglobin levels above 6.0%. These conflicting results 
highlight the importance of investigating differences by 
H. pylori infection status in gastric cancer risk among dia-
betes mellitus patients in future studies.
A key strength of our study is the use of a harmonized, 
high-quality individual-level data to obtain pooled 
estimates, which might have resulted in the very low 
between-study heterogeneity observed in our models 
compared to prior aggregate data meta-analyses. Most 
of our analysis models had I2 below 5% and none had 
above 30%. We used larger samples in our subgroup anal-
yses than used in many previous studies, which ensured 
adequate power for effect size estimation. Moreover, our 
sample was inclusive, coming from eight countries on 
four continents. We had also included H. pylori infec-
tion serostatus, an important factor for gastric cancer, as 
a covariate in our models, in addition to other well-es-
tablished risk factors for gastric cancer, which was rarely 
accomplished in previous studies. The similarity between 
our main results and those from the various sensitivity 
analyses we conducted shows our models were robust.
Our current study also has limitations. We assessed dia-
betes status by self-report, which is known to have high 
specificity but low to moderate sensitivity in some of 
the countries our analysis represents (Espelt et al., 2012; 
Schneider et al., 2012; Goto et al., 2013; Yuan et al., 2015) 
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and might have led to misclassification of the variable. 
However, the use of professional interviewers to admin-
ister questionnaires by most of the studies in our analysis 
could have limited this bias. Also, the prevalence rates of 
diabetes among majority of the controls in our analysis 
were comparable to the respective countries’ averages at 
the time the data were collected. Additionally, the sen-
sitivity of diabetes mellitus self-report is known to be 
education dependent (Yuan et al., 2015) and we adjusted 
for educational status of participants in our models. We 
could have misclassified H. pylori infection status by 
assessing it using antibodies and, for the cases, follow-
ing a gastric cancer diagnosis. Serological diagnosis of H. 
pylori infection, in general, has limited validity (Biranjia-
Hurdoyal and Seetulsingh-Goorah, 2016) and could be 
unreliable at gastric cancer diagnosis as the infection 
tends to diminish with cancer progression (Peleteiro 
et al., 2012). However, the results from our sensitivity 
analysis with H. pylori seropositive controls only in the 
model suggest misclassification of H. pylori infection sta-
tus, if present, was nondifferential for cases. Our results 
were also susceptible to selection bias due to the use 
of hospital controls by most of the studies in our anal-
yses. However, the similarity of ORs between studies 
that used hospital controls and those with controls from 
the general population, as well as across levels of other 
sociodemographic characteristics suggests this bias was 
unlikely to have occurred. Due to absent or limited data, 
we were not able to adjust for other established corre-
lates of diabetes and gastric cancer in our models, includ-
ing medications use, salt intake, glycemic control, family 
history of gastric cancer, and factors known to affect dia-
betes or cancer-related health-seeking behaviors, such as 
mental wellbeing (Peleteiro et al., 2011; Bajaj et al., 2012; 
Tseng and Tseng, 2014; Kabir et al., 2020). However, our 
inclusion of H. pylori infection serostatus, fruit/vegetable 
consumption, and history of gastric ulcer as covariates in 
study-specific logistic regression models is a significant 
improvement in many previous studies.
In conclusion, results from our large pooled analysis of 
individual-level data from 14 international case–control 
studies showed no overall association between diabetes 
and gastric cancer. The subgroup analysis; however, sug-
gested that diabetes could be a risk factor for cardia gastric 
cancer. There is a need for further research to understand 
the underlying mechanism for the dissimilarity in the dia-
betes-associated cardia and noncardia gastric cancer risk.
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